POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management.

For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows. While advances in medical science have significantly improved diagnosis and treatment, the fundamental model has remained largely reactive.

Today, advances in AI, healthcare data and remote monitoring technologies are beginning to reshape this model. Wearable devices and remote patient monitoring ("RPM") technologies can support continuous collection of health indicators outside traditional clinical settings, while longitudinal and real-world healthcare data can provide a broader view of changes in an individual's health status. AI can help analyze these multidimensional datasets, identify potential risk signals and support more timely healthcare decisions.

Pomdoctor believes the convergence of these technologies is enabling healthcare to evolve from "diagnose and treat" toward "predict, alert and intervene," with particular relevance to chronic disease management, where continuous monitoring and timely intervention can play an important role in long-term health management.

Pomdoctor's Role in the Transition to Predictive Healthcare

Against this backdrop, Pomdoctor is positioning its healthcare ecosystem to participate in the transition toward predictive healthcare. The Company's strategy combines its existing healthcare operations and physician resources with AI, wearable technologies, RPM capabilities and real-world healthcare data.

Rather than developing these capabilities independently, Pomdoctor aims to integrate them into a coordinated healthcare management framework in which data generated through monitoring and healthcare interactions can support AI-driven analysis, physician follow-up and more personalized health management.

The Company believes its existing healthcare infrastructure and growing technology capabilities provide a foundation to support a more continuous, data-driven and proactive model of care.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented, "For generations, healthcare has largely focused on treating patients after illness or symptoms appear. New technologies are creating the opportunity to move healthcare intervention further upstream. We believe predictive healthcare will become an increasingly important part of future health management. By combining our healthcare operations, physician resources, real-world data and technology capabilities, we aim to help build the infrastructure needed to support this transition."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company's strategy to participate in the transition of healthcare from a reactive model toward a predictive and proactive model; the Company's plans to integrate AI, wearable technologies, remote patient monitoring ("RPM") capabilities and real-world healthcare data with its existing healthcare operations and physician resources into a coordinated healthcare management framework; the Company's pursuit of the development of a predictive healthcare data and services infrastructure; the Company's belief that its existing healthcare infrastructure and technology capabilities provide a foundation for a more continuous, data-driven and proactive model of care; expectations regarding the future role of predictive healthcare, including in chronic disease management; and the anticipated benefits of the Company's strategy for patients, healthcare providers and other ecosystem participants, including improved healthcare outcomes and long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "aims," "estimates," "projects," "intends," "plans," "pursues," "positions," "will," "would," "should," "could," "may" or other similar expressions. These forward-looking statements are based on the Company's current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company's control.  Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law. 

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties. Investors are urged to review the section entitled "Item 3. Key Information—D. Risk Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2026, and the Company's other filings with the SEC, which are available on the SEC's website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-highlights-the-shift-from-reactive-treatment-to-predictive-healthcare-302905258.html

SOURCE POMDOCTOR LIMITED